S J Santner

Author PubWeight™ 38.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000 3.44
2 Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001 2.28
3 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995 1.88
4 Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000 1.60
5 Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat 2000 1.39
6 The effect of chronic childhood malnutrition on pubertal growth and development. Am J Clin Nutr 1982 1.22
7 In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 1984 1.20
8 Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 1985 1.10
9 Timed urinary gonadotropin measurements in normal infants, children, and adults, and in patients with disorders of sexual maturation. J Pediatr 1977 1.10
10 Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994 1.02
11 Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 1997 1.00
12 Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat 1986 1.00
13 Aromatase activity in primary and metastatic human breast cancer. Cancer 1987 0.92
14 Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab 1983 0.91
15 Prognostic value of breast cancer aromatase. Cancer 1992 0.90
16 Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 1995 0.90
17 Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. Br J Cancer 1985 0.87
18 Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat 1998 0.86
19 A model for validation of radioimmunoassay kit reagents: measurement of follitropin and lutropin in blood and urine. Clin Chem 1981 0.85
20 Regulated CYP19 aromatase transcription in breast stromal fibroblasts. J Clin Endocrinol Metab 2000 0.84
21 Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies. Am J Dis Child 1983 0.84
22 In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Res 1982 0.84
23 Circadian rhythms in gonadotropin excretion in prepubertal and pubertal children. J Clin Endocrinol Metab 1976 0.80
24 Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 1998 0.80
25 Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann N Y Acad Sci 1986 0.78
26 Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase. J Steroid Biochem 1984 0.78
27 Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 1995 0.78
28 17 Beta-hydroxysteroid dehydrogenase in human breast cancer: analysis of kinetic and clinical parameters. Steroids 1989 0.78
29 Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J Steroid Biochem Mol Biol 1996 0.78
30 Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation. Anticancer Res 1984 0.78
31 Responsiveness of gonadotropin secretion to infusion of an opiate-receptor antagonist in hypogonadotropic individuals. J Clin Endocrinol Metab 1982 0.77
32 Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis. Breast Cancer Res Treat 1988 0.77
33 Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 1997 0.76
34 Role of polyamines in the synthesis of prolactin-regulated growth factors by experimental breast cancer in culture. Breast Cancer Res Treat 1987 0.76
35 Gonadotropin excretion during puberty in malnourished children. J Pediatr 1984 0.75
36 Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women. J Lab Clin Med 1987 0.75
37 Potency and specificity of CGS-16949A as an aromatase inhibitor. Endocr Res 1990 0.75
38 Marked heterogeneity of aromatase activity in human malignant melanoma tissue. Eur J Cancer Clin Oncol 1988 0.75
39 Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms. Med Hypotheses 1995 0.75
40 Response of the prepubertal ovary to acute chorionic gonadotropin administration: absence of modulation by growth hormone. J Clin Endocrinol Metab 1985 0.75
41 Perturbations of negative feedback sensitivity in agonadal patients undergoing estrogen replacement therapy. J Clin Endocrinol Metab 1983 0.75
42 The integrated gonadotrophin test. Ann Intern Med 1978 0.75
43 Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat. Cancer Res 1986 0.75
44 Urinary follicle-stimulating hormone during pregnancy: relationship to sex of fetus. J Clin Endocrinol Metab 1979 0.75
45 Pseudoaromatase in circulating lymphocytes. J Steroid Biochem Mol Biol 1993 0.75
46 The assessment of diminished testicular function in boys of pubertal age. Clin Endocrinol (Oxf) 1986 0.75
47 Usefulness of urinary gonadotropin measurements to assess luteinizing hormone releasing factor (LRF) responsiveness in hypogonadotropic states. J Clin Endocrinol Metab 1977 0.75